RxDoctor Payments Data

Courtney Nichols, NP

Family · Kirksville, MONPI 1235645151

Payments from drug & device makers

$4,070in general payments, 2019–2025

Across 273 payments — averaging $14.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$693
  • Novo Nordisk$422
  • Otsuka America Pharmaceutical, Inc.$222
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$201
  • Takeda Pharmaceuticals U.S.A., Inc.$166
  • Amgen$150
  • plus $2K from 43 others

What the payments were for

  • Food & beverage$4,03199%
  • Education$391%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,070 in reported general payments places this provider in the 90th percentile of 3,812 family providers in Missouri.

See all family providers in Missouri

Medicare billing

Part B allowed, 2024
$165,450
Medicare patients
94
Services billed
31,757

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin11$21,321
FarxigaDapagliflozin Propanediol23$18,712
EliquisApixaban18$17,267
OzempicSemaglutide16$15,666
TrulicityDulaglutide12$11,997
Spiriva HandihalerTiotropium Bromide18$9,259
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$7,257
EntrestoSacubitril/Valsartan11$6,675
Spiriva RespimatTiotropium Bromide12$6,226
TrintellixVortioxetine Hydrobromide12$6,028
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$5,606
Breo ElliptaFluticasone/Vilanterol12$4,807
VascepaIcosapent Ethyl23$4,065
Paliperidone ErPaliperidone13$3,238
Celecoxib45$2,343

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Spiriva Respimat$26$27,54623 claims
AstraZenecaFarxiga$112$18,71223 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$124$17,66935 claims
PfizerEliquis$142$17,26718 claims
Novo NordiskOzempic$422$15,66616 claims
Lilly USA, LLCTrulicity$113$11,99712 claims
NovartisEntresto$77$6,67511 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$166$6,02812 claims
AbbVieSynthroid$693$56814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,812 family providers in Missouri.

Other family in Kirksville

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →